A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma
Open Access
- 1 April 2015
- journal article
- Published by SAGE Publications in Acta Radiologica Open
- Vol. 4 (4)
Abstract
Background Overall survival (OS) of patients with hepatic metastases of uveal melanoma is strongly linked with hepatic tumor control. Due to the lack of an effective systemic chemotherapy, locoregional therapies like radioembolization should play an increasingly important role. Purpose To report complications and response rates of radioembolization as salvage therapy for hepatic uveal melanoma metastases. Material and Methods Between October 2006 and January 2014, eight patients (age, 59.1 ± 15.3 years; 5 men) with histologically proven uveal melanoma and hepatic metastases received radioembolization with glass microspheres at a single center. All patients had been heavily pretreated with multiple systemic/locoregional therapies resulting in a long median interval between diagnosis of hepatic metastases and radioembolization (17.1 months; range, 6.4–23.2 months). Follow-up consisted of clinical assessment, laboratory tests and tri-phasic computed tomography (CT) before and 1, 3, 6, 9, and 12 months after radioembolization. Response to therapy was evaluated by CT using RECIST version 1.1 and by survival time. Safety (laboratory and clinical toxicity) was rated according to Common Terminology Criteria for Adverse Events 4.03. Using Kaplan-Meier analysis time to progression of hepatic metastases (hTTP) and OS were calculated. Results One month after radioembolization 50% of patients presented with stable and 50% with progressive disease. Median hTTP and OS after radioembolization were 4.3 weeks (range, 3.4–28.6 weeks) and 12.3 weeks (range, 3.7–62.6 weeks), respectively. Median OS after diagnosis of hepatic metastases was 19.9 months (range, 7.3–31.4 months). Radioembolization was tolerated well in all patients without toxicity higher than grade 2. Conclusion Radioembolization is a safe salvage therapy even in heavily pretreated hepatic metastases of uveal melanoma.Keywords
This publication has 27 references indexed in Scilit:
- Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal MelanomaAmerican Journal of Clinical Oncology, 2016
- Selective internal radiation therapy of hepatic tumours: Is coiling of the gastroduodenal artery always beneficial?Clinical Radiology, 2014
- Transhepatic Therapies for Metastatic Uveal MelanomaSeminars in Interventional Radiology, 2013
- Radioembolization as Salvage Therapy for Hepatic Metastasis of Uveal Melanoma: A Single-Institution ExperienceAmerican Journal of Roentgenology, 2011
- Locoregional Management of Hepatic Metastasis From Primary Uveal MelanomaSeminars in Oncology, 2010
- Yttrium-90 Radioembolization for Liver Malignancies: Prognostic Factors Associated with SurvivalJournal of Vascular and Interventional Radiology, 2010
- Serum markers to detect metastatic uveal melanoma.2007
- Developments in the management of uveal melanomaClinical & Experimental Ophthalmology, 2004
- [Dacarbazine in malignant melanoma. Rare, severe side-effect: Budd-Chiari-syndrome (author's transl)].1982
- Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanomaJournal of Cancer Research and Clinical Oncology, 1979